Shield Therapeutics's market cap is currently ―. The company's EPS TTM is p-0.133; its P/E ratio is -0.16; Shield Therapeutics is scheduled to report earnings on April 25, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Dec 21	Jun 21	Dec 20	Jun 20
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	£ 2.40M	£ 12.12M	£ 22.60M	£ 2.94M	£ 6.51M
Total Assets	£ 35.82M	£ 44.41M	£ 52.41M	£ 32.53M	£ 38.24M
Total Debt	£ 0.00	£ 156.00K	£ 0.00	£ 28.00K	£ 0.00
Net Debt	£ -2.40M	£ -11.96M	£ -22.60M	£ -2.91M	£ -6.51M
Total Liabilities	£ 3.25M	£ 3.38M	£ 1.39M	£ 2.25M	£ 2.77M
Stockholders Equity	£ 32.57M	£ 41.03M	£ 51.01M	£ 30.28M	£ 35.47M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in GBP

Shield Therapeutics Earnings and Revenue History

Income Statement >

Shield Therapeutics Debt to Assets

Balance Sheet >

Shield Therapeutics Cash Flow

Cash Flow >

Shield Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing